Temedica

Name

Temedica

Legal name

Temedica GmbH

Website

https://temedica.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Real-World Evidence & Commercial Analytics Software

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000)

akta.pro primary industry

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

akta.pro secondary industries

Diagnostic & Triage Decision Support (HLACAGAA), Medication Adherence, Reminders & Patient Support (HLACAKAF)

Keywords

• Real-world evidence analytics
• Pharma commercial intelligence
• Omnichannel patient engagement
• Health data platform
• Patient companion apps

Headquarters

HQ city

München

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

1. SaaS Platform Subscriptions: Subscription-based access to Permea Insight Hub, Omnichannel Engagement Suite, and related analytics platforms with configurable dashboards and AI-driven insights for pharmaceutical brand teams
2. Professional Services: Commercial and medical strategic services including market insights analysis, competitive benchmarking, launch excellence strategy, brand strategy, stakeholder engagement, patient journey analysis, real-world evidence generation, and medical communication
3. Patient Companion App Development: Co-development of indication-specific patient companion apps with pharmaceutical partners (Roche, AbbVie, Novo Nordisk) for specific therapy areas including MS, IBD, ophthalmology, and diabetes
4. Scientific Writing Services: Peer-reviewed publication services including clinical manuscripts, posters, e-submissions, and medical communications for regulatory compliance and brand credibility

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Temedica is a tech-, AI-, and data-enabled solution and service provider for the pharmaceutical industry. Its core product is the Permea analytics platform — anchored by the Permea Insight Hub — which combines longitudinal patient-generated health data, insurance claims, prescriptions, and patient-reported outcomes with scientific and commercial sources to deliver GDPR-compliant real-world evidence. Complementing the analytics platform, Temedica sells an Omnichannel Engagement Suite that orchestrates automated, behavior-driven patient and HCP journeys, a portfolio of indication-specific Patient Companion apps (Brisa, Tami, Retinora, Dibi, Clevi Fem), and strategic/medical services such as scientific writing and brand strategy for pharma clients.

Product overview

Temedica operates as a platform-plus-modules architecture offering three core pillars: Permea (AI-powered analytics), Omnichannel Engagement Suite (for HCP and patient engagement), and Services (strategic consulting and scientific writing). The Permea suite includes the Permea Insight Hub as the central configurable analytics platform, supplemented by specialized modules for disease navigation, commercial tracking, and patient-reported outcomes. The Omnichannel Engagement Suite comprises separate HCP and Patient modules, both powered by automated, behavior-driven journey orchestration. The company also develops co-branded Patient Companion apps (Brisa, Tami, Retinora, Dibi) and launched its first owned app, Clevi Fem, in 2025. All offerings are designed for the pharmaceutical industry to improve brand performance through real-world insights, compliant engagement, and medical expertise.

Differentiator

Problem solved

Functional benefit

Brands

• Permea: Analytics platform combining longitudinal patient-generated health data with scientific and commercial sources for GDPR-compliant real-world insights
• Permea Insight Hub
• Permea Disease Navigator
• Permea Commercial Compass
• Permea Patient Voice
• Omnichannel Engagement Suite
• Patient Companion
• Brisa
• Tami
• Retinora
• Dibi
• Clevi

Products and services

• Permea Insight Hub Fully configurable, AI-driven analytics platform that unifies patient, HCP, and market data in role-specific dashboards with drag-and-drop functionality, enabling pharma brand teams to access real-world insights in minutes rather than weeks.
• Omnichannel Engagement Suite Behavior-driven orchestration engine for automated, compliant, personalized patient and HCP journeys across field visits, CRM, email, push, SMS, in-app messages, and webinars, triggering next-best actions from real-time behavior signals.
• Permea Disease Navigator Disease prevalence mapping and diagnostic journey analytics tool identifying high-value regions, tracking diagnostic journeys, and mapping critical care gaps with robust real-time data for optimized resource allocation and brand strategy.
• Permea Commercial Compass Real-time prescription data tracking module with patient-level prescription data arriving 15 days after end of month, enabling monitoring of prescription ramp-ups, switch flows, and competitor activity with source-of-business attribution.
• Permea Patient Voice Real-time patient-reported outcomes (PRO) module funneling data from Patient Companions into dashboards, monitoring over 10,000 data points per patient — from adherence drops to sentiment shifts — for agile commercial and medical strategy updates.
• Patient Companion (co-development program) Co-developed indication-specific patient companion apps for omnichannel patient marketing and personalized journeys, capturing real-time insights, boosting adherence, and driving measurable ROI with go-live in as little as 6 weeks.
• Brisa (Patient Companion for MS) Multiple Sclerosis companion app co-developed with Roche, empowering individuals with MS to track symptoms, gain deeper understanding of their unique MS journey, and identify beneficial practices; reached a 5-year milestone in 2024.
• Tami (Patient Companion for IBD) Patient companion for Inflammatory Bowel Disease (IBD), including ulcerative colitis and Crohn's disease, enabling symptom tracking, disease progression monitoring, and contribution to research efforts.
• Retinora (Patient Companion for retinal diseases) Patient companion for macular and retinal vascular diseases including wet macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusions, helping patients manage conditions by tracking health and goals.
• Dibi (Patient Companion for Type 2 Diabetes) Patient companion for Type 2 Diabetes offering personalized insights, medication tracking, health monitoring tools, and educational resources.
• Clevi Fem First Temedica-owned patient app, launched in 2025 starting with Clevi Fem for menopause health.
• Temedica Services (strategic & medical services) Strategic and tactical services spanning commercial and medical expertise for pharma, including market insights analysis, competitive benchmarking, launch excellence, brand strategy, stakeholder engagement, patient journey analysis, retention and adherence solutions, and medical communications.
• Scientific Writing Expert scientific writing for pharma covering regulatory-compliant, peer-reviewed content from clinical publications to educational pharma materials, integrating real-world evidence and KOL collaboration.

Quantifiable outcome

• +52% faster therapy starts with omnichannel engagement
• +6 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration12 records

AI capability7 records

Feature6 records

Partnerships

13 partnerships are on record, tiered core, major and supporting.

• Google CloudcoreTechnology or Integration · 15 October 2024Co-branded event partnership for 'The Future of Health Insights 2024'; joint presentations on AI in healthcare; Google Cloud hosting for Permea Insight Hub data centers in Germany; AI-powered analytics integration
• Sandoz-HexalmajorStrategic or Co-development Partner · 18 June 2024Landmark webinar series collaboration on multiple sclerosis care; joint research with MS researchers Prof. Dr. med. Tjalf Ziemssen and Prof. Dr. med. Peter Flachenecker; exploring new treatment paradigms and real-world evidence impacts
• Usercentrics GmbHsupportingTechnology or IntegrationConsent Management Platform (CMP) provider for GDPR compliance on website and apps
• ALL-INKL.COM - Neue Medien MünnichsupportingTechnology or IntegrationWeb hosting provider for temedica.com website; servers located in Germany for data compliance
• AdStrive GmbHsupportingTechnology or IntegrationWebsite support and maintenance provider based in Germany
• HubSpotsupportingTechnology or IntegrationMarketing automation platform for email marketing, social media publishing, reporting, contact management, landing pages and contact forms
• Livestorm SASsupportingTechnology or IntegrationVideo conference and webinar platform for conducting interactive live events and meetings
• Google Cloud EMEA LtdcoreTechnology or IntegrationPrimary cloud infrastructure provider for Permea Insight Hub; data centers located in Germany; EU-US Data Privacy Framework participant for cross-border data compliance
• PostHog Inc.supportingTechnology or IntegrationProduct analytics and user behavior analysis platform for Permea Insight Hub optimization; data stored in EU data centers
• Okta Inc. (Auth0)supportingTechnology or IntegrationUser management and authentication/authorization service for Permea Insight Hub; managed servers hosted in Germany
• Brevo GmbH (Sendinblue)supportingTechnology or IntegrationTransactional email service provider for user registration, password resets, and account communications within Permea Insight Hub
• Peaberry Software Inc. (Customer.io)supportingTechnology or IntegrationCommunication automation platform for personalizing and automating emails and messages within patient companion apps; US Data Privacy Framework participant
• Personio GmbHsupportingTechnology or IntegrationHR and applicant tracking software provider for recruiting and employee management

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IQVIA: Global leader in real-world evidence, clinical research, and pharma commercial analytics. Offers the most comprehensive RWE, healthcare data, and technology portfolio for pharma — overlaps with Temedica across analytics, RWE, and patient engagement but at much broader scope.
• Veeva Systems: Dominant cloud platform for pharma commercial operations, including CRM, HCP engagement, and commercial data. Competes directly with Temedica's Omnichannel HCP Engagement Suite and Permea Commercial Compass but with a much broader enterprise footprint.

Direct peers

• Smartpatient: Munich-based company operating the MyTherapy patient companion app and co-developing indication-specific companion apps with pharma partners. The most direct European peer to Temedica's Patient Companion portfolio (Brisa, Tami, Retinora, Dibi) and competes for the same pharma co-development deals.
• Komodo Health: US-based real-world data and analytics platform serving pharma with claims-powered patient journey insights. Direct competitor to Temedica's Permea Disease Navigator and Patient Voice, though primarily US-claims focused versus Temedica's GDPR-compliant European patient-generated data approach.
• Aktana (IQVIA): AI-driven omnichannel engagement orchestration for pharma commercial teams, now part of IQVIA. Direct overlap with Temedica's Omnichannel Engagement Suite in behavior-driven next-best-action recommendations for HCP and patient journeys.
• Tempus AI: AI-powered real-world patient data platform with strong oncology focus, serving pharma with RWE, commercial analytics, and patient engagement tools. Competes for the same pharma RWE budgets as Temedica's Permea platform, with deeper clinical/genomic data.
• Aetion: RWE analytics platform purpose-built for pharma regulatory and commercial decisions. Competes with Temedica's Permea Commercial Compass and Disease Navigator for pharma HEOR, market access, and commercial analytics engagements.
• Medisafe: Medication adherence platform with consumer companion apps and pharma partnerships, including co-developed condition-specific companions. Direct competitor to Temedica's Dibi (diabetes) and other Patient Companion apps focused on adherence outcomes.
• Propeller Health (ResMed): Digital therapeutic and patient companion platform focused on chronic respiratory conditions, with pharma partnerships for adherence and real-world evidence. Comparable in chronic-condition patient engagement, adherence focus, and PRO data capture to Temedica's companion app portfolio.

Others

• Datavant: Healthcare data connectivity and de-identification infrastructure enabling linking of claims, EMR, and patient data. Functions as enabling infrastructure for the RWE category Temedica operates in rather than a direct commercial competitor; strategic partner/acquirer possibility.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInde.linkedin.com/company/temedica

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Temedica